Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Schwab vs Vanguard: Which is the Better Dividend ETF?
10:02am, Monday, 09'th Feb 2026
The Vanguard Dividend Appreciation ETF and the Schwab U.S. Dividend Equity ETF offer different benefits for investors.
Oppenheimer Asset Management Inc. Purchases 32,005 Shares of Bristol Myers Squibb Company $BMY
06:24am, Monday, 09'th Feb 2026
Oppenheimer Asset Management Inc. grew its position in shares of Bristol Myers Squibb Company (NYSE: BMY) by 6.4% during the undefined quarter, according to the company in its most recent filing with
Candriam S.C.A. Cuts Stake in Bristol Myers Squibb Company $BMY
05:02am, Monday, 09'th Feb 2026
Candriam S.C.A. decreased its position in Bristol Myers Squibb Company (NYSE: BMY) by 10.5% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence
01:00am, Monday, 09'th Feb 2026
BAAR, Switzerland--(BUSINESS WIRE)--Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence.
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY
04:40am, Saturday, 07'th Feb 2026
Birmingham Capital Management Co. Inc. AL lowered its stake in shares of Bristol Myers Squibb Company (NYSE: BMY) by 55.6% in the undefined quarter, according to the company in its most recent 13F fil
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
04:39pm, Friday, 06'th Feb 2026
Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with ma
Bristol Myers Squibb Q4 Earnings Call Highlights
04:26am, Friday, 06'th Feb 2026
Bristol Myers Squibb (NYSE: BMY) executives emphasized "focused execution" in 2025 and pointed to continued momentum entering 2026, as the company's growth portfolio increasingly offsets declines in l
Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade
07:26pm, Thursday, 05'th Feb 2026
Chris Boerner, Bristol Myers Squibb CEO, joins CNBC's "Power Lunch" to discuss the company's quarterly earnings results, the drug pipeline and much more.
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
06:04pm, Thursday, 05'th Feb 2026
Bristol-Myers Squibb Company (BMY) Q4 2025 Earnings Call Transcript
Why Bristol Myers Squibb Stock Topped the Market Today
05:11pm, Thursday, 05'th Feb 2026
Investors were impressed by the company's performance in the final quarter of 2025. It beat analyst expectations on both the top and bottom lines.
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
12:23pm, Thursday, 05'th Feb 2026
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.
Weekly Jobless Claims Exceed Expectations
12:10pm, Thursday, 05'th Feb 2026
Weekly Jobless Claims Exceed Expectations.
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
11:51am, Thursday, 05'th Feb 2026
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
Jobless Claims Pop Up a Bit, Major Morning for Earnings
11:36am, Thursday, 05'th Feb 2026
Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.
Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet
10:50am, Thursday, 05'th Feb 2026
Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion.
